|
Tuesday 14th October 2008
|
8.30am | Registration and welcome coffee
|
8.50am | Opening remarks and welcome from the Chair
Prof Robert Booy, Head of Clinical Research, National Centre for Immunisation Research and Surveillance
|
| A GLOBAL PERSPECTIVE AND LOCAL MARKET OUTLOOK |
|
9am | The new era of adjuvant systems
- Broadening vaccine development beyond antigen research to adjuvanted products
- A new generation of more powerful adjuvants
- Identifying the benefits of rapid induction and dose sparing
capability delivered in pandemics
Dr Nathalie Garcon VP, Head of Global Adjuvant Centre for Vaccine Development, GSK Biologicals
|
9.25am | The ongoing revolution in global vaccinology
- Developing global vaccine approaches for global immunisation needs
- Overcoming the obstacles to the development and global
distribution of vaccines
- What does the future hold for international immunisation
programs?
Sir Gustav Nossal, Chair Strategic Advisory Council,
Children’s Vaccine Program, PATH
|
9.50am | Industry expert panel session: Comparing the Australian market to the global vaccine economy
- Analysing the local market size, drivers and growth dynamics
- Which vaccines present the greatest investment opportunities in Australia?
- Leveraging Australia’s position as a global leader in conducting clinical trials
Andrew Goodsall, Senior Healthcare Analyst, UBS
|
10.20am | Morning tea and Speed Networking
|
| OPPORTUNITIES AND CHALLENGES INVACCINE FUNDING |
|
11.30am | Investing in vaccines for developing countries: ethical
partnering for profitability
- Examining the profitability of investing in developing countries
- Analysing efforts to incentivise the industry
- Which is the most successful approach?
Dr Mansour Yaich, Vaccine Development Director, PATH
|
11.55am | Panel session: Investing in orphan vaccines
- Why is the industry hesitant to invest in orphan vaccines?
- Incentivising the development of orphan vaccines
- Examining legislation designed to overcome the disincentives
to developing orphan vaccines
Dr MansourYaich, Vaccine Development Director, PATH
Dr Satish Ravetkar, Senior Director, Serum Institute of India
Sir Gustav Nossal, Chair Strategic Advisory Council,
Children’s Vaccine Program, PATH
|
12.35pm | Networking lunch
|
| GOVERNMENT, POLICY AND REGULATORY ISSUES |
|
1.35pm | Policy considerations for adult vaccines in Australia
- Examining the gaps in the Australian National Immunisation Schedule presented by adult vaccines
- Incorporating boosters and adult vaccines into the Australian
immunisation strategy
- Implications of adult vaccines for a whole-of-life registry
Prof. Raina MacIntyre, Head of School for Public Health and Medicine, University of New South Wales
|
2pm | E-health- revolutionising healthcare in Australia
- How national e-health initiatives will support a national immunisation registry:
- Individual Electronic Health Records
- Unique Healthcare Identifies
- National Producr Catalogue
- Clinical Terminologies
Karen Gibson, General Manager, National E-Health
Transition Authority
|
2.35pm | National immunisation KOLs panel session: Designing the best national immunisation strategy
- Reviewing Immunise Australia Program updates
- Streamlining the process of introducing novel vaccines to
National Immunisation Schedule
- Maintaining the high level of public access to vaccines in the
Australian market
Assoc Prof Rajiv Khanna, Director, Australian Centre for Vaccine Development
Prof David Isaacs, Member, ATAGI and PBAC
|
2.55pm | Afternoon tea
|
| BUILDING PARTNERSHIPS AND EVOLVING BUSINESS MODELS
|
|
3.25pm | Partnering for success: The vaccine development model
- How can small biotechs and big pharma work together to produce vaccines quickly and economically?
- Engaging as a research partner as opposed to a mere investor
- What is the optimal stage in the development process to
partner?
Dr Daniel Grant, Head Strategic Alliances ANZ, Pfizer
|
3.50pm | Adopting a partnership and exchange approach with
overseas companies
- Collaborating with overseas manufacturers to streamline vaccine production
- How to partner with offshore companies in a technology
transfer relationship
- Examining the benefits of importing vaccines in an epidemic
Dr Satish Ravetkar, Senior Director, Serum Institute of India
|
4.15pm | Biotech innovators panel: Building a successful product portfolio: innovating for future growth
- Balancing vaccine development portfolios to maximise profitability whilst minimising risk
- Developing a sustainable R&D pipeline delivering the optimal
cost-effective vaccines
- Proactively identifying targets for a global portfolio
- Effective design and implementation of clinical trials to demonstrate safety and efficacy of new vaccine products
Dr Andrew O’Brien, MD, BioDiem
Assoc Prof David Anderson, PhD, NHMRC Senior Research Fell, Deputy Director Macfarlane Burnet Institute for Medical Research and Public Health
Sarah Reading, Associate Director Project Management, Quintiles Pty Ltd (Australia & NZ)
|
4.55pm | End of Day One and networking drinks
|
|
Wednesday 15th October 2008
|
8.30am | Welcome coffee
|
8.50am | Opening remarks and welcome from the Chair
Assoc Prof Rajiv Khanna, Director, Australian Centre for Vaccine Development
|
| THE NEXT GENERATION OFVACCINES |
|
9am | Developing a universal influenza vaccine
- Is a universal influenza vaccine within reach?
- Reviewing global approaches
- Examining the latest results from human trials of the M2ebased
vaccine
Dr Ian Barr, Deputy Director, WHO Centre for Influenza
|
9.30am | Therapeutic immunisation: where are we heading?
- Therapeutic vs. prophylactic vaccines: where does the future of the vaccine market lie?
- Enhancing responses to multidrug therapy and reducing
frequency of relapses
- Therapeutic vaccines for HIV, hepatitis B, malaria,
tuberculosis and autoimmune diseases
Dr Ian Frazer, Director, Diamantina Institute for Cancer
|
10am | Are new vaccination strategies needed to control the emergence of Adult Pertussis
- Examining the global emergence of Pertussis despite the high vaccine coverage reates
- Adolescents and adults- the major source of Pertussis transmission to infants at risk of severe morbidity and mortality
- What vaccine strategies are needed for adequate control
Dr Helen Marshall, Director, Paediatric Trials Unit, Women's and Children's Hospital Lecturer, Discipline of Paediatrics and Lecturer, Discipline of Public Health, University of Adelaide
|
10.30am | Morning tea
|
| AN UPDATE OF GLOBAL VACCINE PRIORITIES |
|
11am | Examining avian flu pandemic strategies
- Collaborating between stakeholders to ensure seasonal and pandemic influenza vaccine supply
- Utilising emerging vaccine technologies to speed up influenza
vaccine production in a pandemic
- How ready are we for an avian flu pandemic?
Dr Klaus Stohr, Director, Influenza Vaccine Franchises, Novartis
|
11.30am | Updating developments in AIDS vaccine research
- Identifying the most promising vaccines in clinical trials
- Coordinating R&D efforts across multiple research centres
- Working together in developing an AIDS vaccine
Dr Ian Gust, Chair Scientific Advisory Board, International AIDS Vaccine Initiative
|
12pm | Networking lunch
|
| DEVELOPMENTS IN DELIVERY SYSTEMS AND ADJUVANTS |
|
1pm | New paradigms and market opportunities in use of novel
adjuvants to rejuvenate old vaccines
- Utilising new adjuvants to protect patents on old vaccines
- Overcoming the regulatory issues of increased reactogenicity
- Considering the impact of emerging adjuvants on vaccine
development
Prof Nikolai Petrovsky, Chairman, Vaxine
|
1.30pm | ISCOMATRIX™ Adjuvant: Science, Supply and Safety
Addressing the challenges to pave the way for a novel adjuvant with broad applications
- Maintaining public confidence in vaccines through balancing benefit with public concerns and perceptions
- Assisting in informing the risk versus benefit assessment prior to clinical trials with a strong scientifically justified rationale
- The product evaluated in clinical trials must translate to the product proposed for registration and commercial supply
- Safety databases and signal detection - understanding the safety profile
Jillian Bennet, Head of Regulatory Affairs, CSL Limited
|
2pm | Investing in mucosal immunisation: the path to product
- Examining the latest clinical research into mucosal delivery systems
- Understanding the difficulties in developing a commercially
viable mucosal immunisation strategy?
- Identifying which vaccines will be best delivered by mucosal
routes
Prof Allan Cripps, Pro Vice Chancellor Health, Griffith
University
|
| STREAMLINING VACCINE PRODUCTION AND DISTRIBUTION FOR
THE FUTURE |
|
2.30pm | Learning lessons from the EI outbreak: vaccine selection,
acquisition, and delivery in an emergency
- Preparing for emergency outbreaks by ensuring availability
- Collaborating with manufacturers to ensure steady supply
- Managing the cold chain for quality and reliability
- Using a GM product: auditing and training considerations
Ian Denney, Manager Veterinary Services, Animal Health Australia
|
3pm | Afternoon tea
|
3.30pm | Innovative technologies to improve vaccine development and production
- Analysis of traditional development and processing processes
- Process compression using innovative technologies in clarification, ultrafiltration and fluid handling
- Advances in sterile processing of adjuvant and liposomal preparations
- Increasing regulatory compliance and speeding process development using disposable technologies
Michael Payne, Knowledge Development Manager, Millipore
|
4.30pm | Panel session: Future prospects for the global vaccines market
- Emerging threats to the global vaccines industry
- Future of government immunisation legislation
- Global strategies for the international markets
Hugues Bogaerts MD FFPM, Vice President and Senior Medical Director, GlaxoSmithKline (Belgium)
Dr MansourYaich, Vaccine Development Director, PATH
Prof Robert Booy, Head of Clinical Research, National Centre for Immunisation Research and Surveillance
|
4.40pm | Closing remarks and close of conference
|
